Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Edoxudine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.62 |
| ▸ | TK1 | P04183 | 3/20 | 0.78 |
| ▸ | TK2 | O00142 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edoxudine SCHEMBL21389875 | 0.95 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL1254185 | 0.95 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL65580 | 0.95 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL12370767 | 0.95 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL65579 | 0.95 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL5983091 | 0.95 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL5983087 | 0.95 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Edoxudine SCHEMBL9408693 | 0.95 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Phosphoric Acid SCHEMBL3241651 | 0.92 | TK1 (0.92) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| Phosphoric Acid SCHEMBL16053559 | 0.92 | TK1 (0.72) | TK1TK2LMNASMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4271153-A | VIRICIDES - TO COMBAT HERBES VIRUS | ROBUGEN GMBH PHARMAZEUTISCHE FABRIK (DE) | 1981-06-02 | — | — | US | claimed |